Clinical Trials Directory

Trials / Completed

CompletedNCT00963040

Effect of Intranasal Oxytocin on Headache in Chronic Daily Headache

The Effect of Intranasal Oxytocin on Headache Intensity and Headache-associated Symptoms in Patients Suffering From Chronic Daily Headache

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
60 (actual)
Sponsor
MedVadis Research Corporation · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The objective of this prospective, randomized, double-blind, parallel-group, placebo-controlled study is to determine the effectiveness of intranasal oxytocin in subjects suffering from chronic daily headache.

Detailed description

The TI004 and TI005 studies both used a randomized, double-blind, placebo-controlled, parallel-group study design. A protocol-specified interim analysis was performed after completion of the first 40 subjects, resulting in termination of the TI004 study and development of the TI005 protocol, which included the following changes from the TI004 protocol: 1. Increase in oxytocin dose from 32 to 64 IU; 2. Extension of the in-clinic observation period from 2 hours post-dose to 4-hours post-dose; 3. Reduction in sample size from 40 to 20 subjects; 4. Elimination of the laboratory measurements during the screening visit, allowing V1 and V2 potentially to be combined, expediting study completion; 5. Adding in-clinic observation and assessment at 3 hours and 4 hours post-dose and out-of-clinic assessment at 8 hours post-dose. The primary outcome measure is the reduction in headache intensity after drug administration; secondary outcome measures are the headache symptoms, nausea, vomiting, photophobia, and phonophobia. Additional secondary outcome measures are intake of rescue medication and patient satisfaction over a period of 24 hours.

Conditions

Interventions

TypeNameDescription
DRUGSyntocinon4 actuations in each nostril for a total dose of 32 IU
DRUGSterile water4 actuations in each nostril
DRUGSyntocinon8 actuations in each nostril for a total dose of 64 IU
DRUGSterile water8 actuations in each nostril

Timeline

Start date
2009-11-01
Primary completion
2010-08-01
Completion
2010-08-01
First posted
2009-08-20
Last updated
2023-06-15
Results posted
2023-06-15

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00963040. Inclusion in this directory is not an endorsement.